BackAdhera Therapeutics Overview

Adhera Therapeutics EBIT

Track Adhera Therapeutics's EBIT ($-940K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$2.93M
↓ 313.4% YoY

As of Sep 30, 2023

Annual EBIT (TTM)

-$938.00K
↓ 26.93% YoY

Trailing 12 months ending Sep 30, 2023

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Adhera Therapeutics (ATRX) FAQ

Adhera Therapeutics posts a EBIT of $-940K as of September 2023. That compares with $-740K in the prior-year period — down 26.9% year over year. That is below the Healthcare sector average of $1.9T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Adhera Therapeutics's EBIT was $-740K. The latest reading is $-940K — a 26.9% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $1.9T is typical. Adhera Therapeutics's $-940K is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Adhera Therapeutics's financial statement story. At $-940K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ATRX's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $1.9T), and (3) consistency with growth and profitability. This page covers the first two; Adhera Therapeutics's other metric pages and overview cover the third.